Nickerson H D, Colledge W H
Physiology Department, University of Cambridge, Downing Street, Cambridge, UK.
Gene Ther. 2004 Sep;11(17):1351-7. doi: 10.1038/sj.gt.3302311.
Somatic gene repair of disease-causing chromosomal mutations is a novel approach for gene therapy. This method would ensure that the corrected gene is regulated by its endogenous promoter and expressed at physiological levels in the appropriate cell types. A reporter mouse, Gtrosa26(tm1Col), was generated by targeting a mutated LacZ gene to the Rosa26 locus in mouse embryonic stem (ES) cells. The LacZ gene contains a G to A point mutation, resulting in a Glu to Lys amino-acid substitution at position 461, which abrogates enzymatic activity. The gene is expressed in ES cells, primary embryonic fibroblasts, and in all tissues examined in the adult mouse, including the lung, liver, kidney, spleen, heart, brain and smooth muscle. This transgenic mouse will allow testing of gene repair strategies in vivo and identification of which cell types can be successfully targeted by chromosomal gene repair. Although low levels of gene repair were achieved in the ES cells used to generate the Gtrosa26(tm1Col) mouse, preliminary attempts at gene repair in vivo were unsuccessful, thus highlighting the difficulties that will have to be overcome to get this approach to work.
对致病染色体突变进行体细胞基因修复是一种新型基因治疗方法。该方法可确保校正后的基因受其内源启动子调控,并在适当的细胞类型中以生理水平表达。通过将突变的LacZ基因靶向小鼠胚胎干细胞(ES细胞)中的Rosa26位点,构建了一只报告小鼠Gtrosa26(tm1Col)。LacZ基因存在一个从G到A的点突变,导致第461位氨基酸由谷氨酸替换为赖氨酸,从而消除了酶活性。该基因在ES细胞、原代胚胎成纤维细胞以及成年小鼠的所有检测组织(包括肺、肝、肾、脾、心、脑和平滑肌)中均有表达。这种转基因小鼠将有助于在体内测试基因修复策略,并确定哪些细胞类型能够成功地被染色体基因修复靶向。尽管在用于构建Gtrosa26(tm1Col)小鼠的ES细胞中实现了低水平的基因修复,但体内基因修复的初步尝试未获成功,这凸显了要使该方法发挥作用必须克服的困难。